Source comparison
The Clinical Truth About GHRP-2 vs Tesamorelin + Ipamorelin
Here's the honest answer: GHRP-2 was a breakthrough in the 1990s, but its non-selective mechanism creates research validity problems that modern peptide blends solve. The cortisol and prolactin elevation isn't a minor side effect. It's a confounding variable t
This comparison does not assign a generated winner or score.
- Here's the honest answer: GHRP-2 was a breakthrough in the 1990s, but its non-selective mechanism creates research validity problems that modern peptide blends solve. The cortisol and prolactin elevation isn't a minor side effect. It's a confounding variable that undermines metabolic research. If your protocol measures fat loss, insulin sensitivity, sleep architecture, or cognitive function, elevated cortisol directly influences every one of those endpoints. You're not studying isolated GH effects; you're studying GH plus chronic stress hormone exposure.
- The tesamorelin + ipamorelin blend costs more and requires more peptide mass per cycle, but it delivers what GHRP-2 cannot: receptor-selective GH pathway activation without endocrine noise. The evidence is particularly strong for visceral fat research. Tesamorelin's GHRH mechanism produces VAT reduction that GHRP-2 has never replicated in controlled trials, likely because GHRP-2's cortisol effect promotes central adiposity even as GH promotes peripheral lipolysis.
- For short-term mechanistic studies (≤7 days) where you're measuring immediate receptor responses, GHRP-2 remains viable. For everything else. Body composition, metabolic health, neuroprotection, wound healing. The blend is the defensible choice. The research community has moved toward receptor-selective combinations for a reason.